Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nat Rev Dis Prim. 2021;7(1):88.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Cancer J Clin. 2023;73(1):17–48.

Article  Google Scholar 

Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. Cancer J Clin. 2022;72(5):409–36.

Article  Google Scholar 

Cai Y, Wang B, Xu W, Liu K, Gao Y, Guo C, et al. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Curr Med Chem. 2021;28(42):8755–81.

Article  CAS  PubMed  Google Scholar 

Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–28.

Article  PubMed  Google Scholar 

Mestrallet G, Brown M, Bozkus CC, Bhardwaj N. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors. Front Immunol. 2023;14:1210164.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell. 2018;33(4):690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74–88.

Article  CAS  PubMed  Google Scholar 

Pedroza-Garcia JA, Xiang Y, De Veylder L. Cell cycle checkpoint control in response to DNA damage by environmental stresses. Plant J. 2022;109(3):490–507.

Article  CAS  PubMed  Google Scholar 

Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: i have a DREAM. Cell Death Differ. 2018;25(1):114–32.

Article  CAS  PubMed  Google Scholar 

Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Rev Mol Med. 2020;22: e2.

Article  CAS  PubMed  Google Scholar 

Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MA, Wang X, et al. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell. 2010;40(1):34–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matheson CJ, Backos DS, Reigan P. Targeting WEE1 kinase in cancer. Trends Pharmacol Sci. 2016;37(10):872–81.

Article  CAS  PubMed  Google Scholar 

Barnaba N, LaRocque JR. Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma. Cell Cycle. 2021;20(11):1041–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Nonneville A, Finetti P, Birnbaum D, Mamessier E, Bertucci F. WEE1 dependency and pejorative prognostic value in triple-negative breast cancer. Adv Sci. 2021;8(17):2101030.

Article  Google Scholar 

Zhang W, Li Q, Yin R. Targeting WEE1 kinase in gynecological malignancies. Drug Des Dev Ther. 2024;18:2449–60.

Article  Google Scholar 

Yap TA, Ngoi N, Dumbrava EE, Karp DD, Ahnert JR, Fu S, et al. NCI10329: Phase Ib sequential trial of agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. Eur J Cancer. 2022;174:7.

Article  Google Scholar 

Cai SX, Ma N, Wang X, Jiang Y, Zhang H, Guo M, et al. Discovery and development of a potent and highly selective WEE1 inhibitor IMP7068. Cancer Res. 2023;83(7):ND07.

Google Scholar 

Schutte T, Embaby A, Steeghs N, van der Mierden S, van Driel W, Rijlaarsdam M, et al. Clinical development of WEE1 inhibitors in gynecological cancers: a systematic review. Cancer Treatment Rev. 2023;115:102531.

Article  CAS  Google Scholar 

Yap TA, Miller C, Stenehjem D, Brown EJ, Carleton M, Mirza NQ. First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations. Cancer Res. 2024;84(7):CT195.

Article  Google Scholar 

Merry C, Fu K, Wang J, Yeh IJ, Zhang Y. Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle. 2010;9(2):279–83.

Article  CAS  PubMed  Google Scholar 

Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 2008;98(3):523–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed S, Alam W, Aschner M, Alsharif KF, Albrakati A, Saso L, et al. Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy. Biomed Pharmacot. 2022;155:113797.

Article  CAS  Google Scholar 

Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400-16.e11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A. 2004;101(12):4164–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

Article  PubMed  PubMed Central  Google Scholar 

Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018;9(1):5361.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen J, van Vugt M, de Vries EGE, et al. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer. J Natl Cancer Inst. 2017;109(1):jw192.

Article  Google Scholar 

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.

Article  PubMed  PubMed Central  Google Scholar 

Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.

Article  PubMed  Google Scholar 

Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25–39.

Article  CAS